logo
Want to eat that cookie guilt-free? Here is the best time to do it

Want to eat that cookie guilt-free? Here is the best time to do it

India Today4 days ago
If your day feels incomplete without a sweet treat, you're not alone. But before you reach for that cookie or slice of cake, here's something worth knowing: what you eat before sugar can actually decide how your body handles it.Experts say that increasing the intake of protein and fibre or just having a proportionate size of it to your meals can reduce your craving for sweets and prevent a sharp spike in blood glucose levels, the notorious 'sugar spike' that's often followed by a sluggish crash.advertisementWhen you eat sugary foods or refined carbohydrates, your blood sugar (sugar present in the blood used for energy) rises quickly, this is called a glucose spike. Over time, frequent spikes make your body work harder to control sugar, leading to insulin resistance, weight gain, and even diabetes.
It's like overloading your system again and again until it stops coping well.'Think of protein and fibre help slow down how fast sugar gets into your bloodstream, keeping things in control,' says Neelanjana Singh, author and nutritionist. 'If you eat sugar on an empty stomach, it goes straight to the blood. But if you've had, say, some dal or eggs and veggies first, the sugar is absorbed more gradually.'BLUNTING SUGAR SPIKECarbohydrates, especially refined ones like sweets, breads, and sugary drinks, break down quickly into glucose. This causes a rapid spike in blood sugar, which can then drop quickly, triggering hunger, cravings, and even irritability.But meals rich in protein (like dal, chola, rajma, eggs, tofu, or chicken and fish) and fibre (like vegetables, whole grains, or chia seeds) can 'blunt' this spike by slowing digestion and the absorption of glucose.This effect has been backed by studies showing that a balanced plate can prevent the glucose rollercoaster and even help with long-term weight management and diabetes prevention.WHEN IS THE RIGHT TIME TO HAVE SUGAR?Surprisingly, there is a right time. 'If you're going to have something sweet, the best time is after a full meal that includes protein and fibre,' Neelanjana says. 'This reduces the glucose surge and also satisfies you enough to avoid overeating dessert.'But the worst time? First thing in the morning, on an empty stomach, or between meals when you're hungry. That's when your blood sugar is most likely to spike and crash.Another practice is meal sequencing, or the practice of eating food in a specific order. The idea is simple: eat vegetables first, protein and fats next, and save carbohydrates for last.This, researchers say, can lead to smaller post-meal glucose spikes and improved metabolic health.This eating order has a domino effect on digestion. When protein and fat are eaten before carbs, they slow gastric emptying, meaning food leaves the stomach more slowly.advertisementCarbohydrates then trickle into the bloodstream gradually instead of spiking all at once, which eases the demand on insulin and reduces stress on the pancreas.'It also triggers incretin hormones like GLP-1, which enhance insulin secretion in a glucose-dependent manner and suppress glucagon,' says Shreya Divadkar, Clinical Dietician at Surya Mother and Child Super Speciality Hospital, Pune.Over time, this can help reduce insulin resistance and support long-term blood sugar stability, particularly for people with pre-diabetes or type 2 diabetes.And if you still want dessert, go for it, just clothe it with some protein and fibre first.- EndsMust Watch
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What are GLP-1 drugs, why are they used for weight loss?
What are GLP-1 drugs, why are they used for weight loss?

India Today

time12 hours ago

  • India Today

What are GLP-1 drugs, why are they used for weight loss?

What are GLP-1 drugs, why are they used for weight loss? Credit: Getty Images GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which regulates blood sugar and appetite. What are GLP-1 drugs? These drugs were first developed to manage type 2 diabetes by helping the pancreas release insulin after meals. Originally for diabetes GLP-1 drugs slow down digestion, reduce hunger, and make people feel full faster, leading to reduced calorie intake. How they aid weight loss Popular names include Semaglutide (sold as Ozempic, Wegovy) and Tirzepatide (sold as Mounjaro, Zepbound). Common GLP-1 brands Most GLP-1 drugs are taken as weekly or daily injections, though oral versions like Rybelsus also exist. How they're taken Clinical trials show people can lose 10–20% of body weight when combined with diet and lifestyle changes. Weight loss results Common side effects include nausea, vomiting, constipation, and, in rare cases, pancreatitis or gallstones. Side effects to know GLP-1s are not advised for those with certain thyroid cancers or a family history of such conditions. Not for everyone Doctors emphasise these are not magic bullets—they work best with medical supervision, nutrition, and exercise. Part of a bigger plan

Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients
Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients

Time of India

time16 hours ago

  • Time of India

Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients

Lilly said that it will submit the results to the global regulatory authorities by the end of this year. Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, reducing mortality and cardiovascular risks. The SURPASS-CVOT trial revealed Mounjaro's superiority over Trulicity, showing improvements in A1C levels, weight loss, and renal function. These findings support Mounjaro as a potential front-line therapy, with Lilly planning to submit the results to global regulatory authorities. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Pharma major Eli Lilly today said that it's weight loss drug Mounjaro has helped in reducing cardiovascular risks in patients with Type 2 diabetes and heart to the results of the trial which included over 13,000 patients across 30 countries, including India, 16 % reduction in all-cause mortality was seen, 8% lower risk of heart attack, stroke, or cardiovascular death, reinforcing its potential as a breakthrough therapy for Indians living with type 2 diabetes and heart disease.'Lilly's Mounjaro ( tirzepatide ) has shown superior cardiovascular protection over Trulicity in the landmark SURPASS-CVOT global trial,' it said in a trial also demonstrated significant improvements in A1C (-1.73%) and weight loss (-11.43 kg) for Mounjaro. A1C is a biomarker for Type 2 (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed a definitive cardiovascular benefit in the REWIND study.'In SURPASS-CVOT, Mounjaro achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE- 3), including cardiovascular death, heart attack or stroke vs. Trulicity. In addition, Mounjaro showed improvements on key measures of A1C, weight, renal function and all-cause mortality,' it further trial lasted more than four and a half years and is the largest and longest study of tirzepatide to date.'Cardiovascular disease continues to be the leading cause of death among individuals with type 2 diabetes,' said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). 'The SURPASS-CVOT trials highlight that Mounjaro maintains the cardioprotective effects seen with Trulicity, a GLP-1 receptor agonist, while offering additional advantages such as a slower eGFR decline and a lower mortality rate. These results further support Mounjaro's potential as a front-line therapy for people managing both type 2 diabetes and cardiovascular conditions."Doctors say the results of the study will help the company secure label expansions to reduce the risk of cardiovascular heart-helping benefits of GLP-1 drugs have been well established. Earlier in 2020, lilly's rival Novo Nordisk's Ozempic was approved to reduce cardiovascular risks in Type 2 diabetes patients by the said that it will submit the results to the global regulatory authorities by the end of this year. In September, the company will present detailed data from the trial at the European Association for the Study of Diabetes annual meeting in Vienna.

Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients
Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients

Economic Times

time16 hours ago

  • Economic Times

Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients

Synopsis Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, reducing mortality and cardiovascular risks. The SURPASS-CVOT trial revealed Mounjaro's superiority over Trulicity, showing improvements in A1C levels, weight loss, and renal function. These findings support Mounjaro as a potential front-line therapy, with Lilly planning to submit the results to global regulatory authorities. Agencies Lilly said that it will submit the results to the global regulatory authorities by the end of this year. Pharma major Eli Lilly today said that it's weight loss drug Mounjaro has helped in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease. According to the results of the trial which included over 13,000 patients across 30 countries, including India, 16 % reduction in all-cause mortality was seen, 8% lower risk of heart attack, stroke, or cardiovascular death, reinforcing its potential as a breakthrough therapy for Indians living with type 2 diabetes and heart disease. 'Lilly's Mounjaro (tirzepatide) has shown superior cardiovascular protection over Trulicity in the landmark SURPASS-CVOT global trial,' it said in a trial also demonstrated significant improvements in A1C (-1.73%) and weight loss (-11.43 kg) for Mounjaro. A1C is a biomarker for Type 2 diabetes. Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed a definitive cardiovascular benefit in the REWIND study. 'In SURPASS-CVOT, Mounjaro achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE- 3), including cardiovascular death, heart attack or stroke vs. Trulicity. In addition, Mounjaro showed improvements on key measures of A1C, weight, renal function and all-cause mortality,' it further trial lasted more than four and a half years and is the largest and longest study of tirzepatide to date.'Cardiovascular disease continues to be the leading cause of death among individuals with type 2 diabetes,' said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). 'The SURPASS-CVOT trials highlight that Mounjaro maintains the cardioprotective effects seen with Trulicity, a GLP-1 receptor agonist, while offering additional advantages such as a slower eGFR decline and a lower mortality rate. These results further support Mounjaro's potential as a front-line therapy for people managing both type 2 diabetes and cardiovascular conditions."Doctors say the results of the study will help the company secure label expansions to reduce the risk of cardiovascular heart-helping benefits of GLP-1 drugs have been well established. Earlier in 2020, lilly's rival Novo Nordisk's Ozempic was approved to reduce cardiovascular risks in Type 2 diabetes patients by the said that it will submit the results to the global regulatory authorities by the end of this year. In September, the company will present detailed data from the trial at the European Association for the Study of Diabetes annual meeting in Vienna.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store